PPT-Stroke or systemic embolic events in large NOAC trials, vs

Ruff et al The Lancet 2013 Ruff et al The Lancet 2013 Secundary efficacy and safety outcomes in large NOAC trials vs warfarin Ruff et al The Lancet 2013 Major bleeding events in large NOAC trials vs warfarin. Analysis. A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting . Debbie Summers, MSN, RN, ACNS-BC, CNRN, SCRN, FAHA, ANVP. Saint Luke’s Hospital . Kansas City, MO . Speaker: Debbie Summers . Topic: 2015 ISC Hot Topics- Advancing Your Stroke Program. Disclosure: . Presentation Outline. Introduction to the Topic. 10/27/09 Richmond, CA — Twenty present at gang rape outside school dance. 10/4/13 Philadelphia, . PA . — Two . teens wounded in shooting after high school football . valvular. Atrial Fibrillation. :. Left Atrial Appendage Closure versus Warfarin. Matthew . J . Price. 1. , . Stacey L . Amorosi. 2. , Shannon . O . Armstrong. 3. , Meghan . B Gavaghan. 3. , Douglas Gibson. Important Considerations . as TAVR Moves to . Lower-Risk Patients. Benjamin Z Galper MD MPH. Brigham & Women’s Hospital Boston MA. Consequences of Stroke. Mortality. – TAVR patients suffering a VARC-2 disabling stroke have significantly higher mortality rates compared to patients without stroke. 1-year mortality of 67% vs. 12% and 2-year mortality of 83% vs. 20%.. Professor & Vice-Chairman Department of Neurosurgery. Director Neurosurgical Stroke Service, . Kaleida. Health. Chief Medical Officer, Jacobs Institute. Presenting endorsed statement from. American Association of Neurological Surgeons (AANS). in Acute Stroke. Gregory W. Albers, MD: . Time is Brain. Lee H. Schwaam, MD: . Improving Transport of the Stroke Patient to Hospital. Ameer E. Hassan, DO: . Streamlining Door-to-t-PA Time. Daniel H. Sahlein, MD: . (stroke). Made by : . Dani. . mamo. . Cerebrovascular diseases. *. Cerebrovascular diseases include some of the most common and devastating disorders:. 1-ischemic stroke. 2-hemorrhagic stroke. *. and cerebrovascular anomalies such as :. Meta-Analysis of NOACs vs Warfarin. RCT vs Real-World Data. Screening for Atrial Fibrillation to Prevent Strokes. Silent AF. Screening for AF. Devices for Long-Term AF Screening. Regular Pulse Check for Detecting AF. Anticoagulants.  . Warfarin. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. Target. Vitamin K . epaxide. Thrombin. Xa. Xa. Xa. Administration. Once daily. Twice daily . Once daily. Twice daily. Once daily. Debbie Summers, MSN, RN, ACNS-BC, CNRN, SCRN, FAHA, ANVP. Saint Luke’s Hospital . Kansas City, MO . Speaker: Debbie Summers . Topic: 2015 ISC Hot Topics- Advancing Your Stroke Program. Disclosure: . 60 . yo. smoking, . htn. , . hlpd. , DM presents with right sided weakness. . Patient 1. Patient 2. This matters for secondary stroke prevention. All our work up is figure out etiology only. TOAST Classification. Outcomes. . From. A . Randomized. Trial . of. . Left. . Atrial. . Appendage. . Closure. Versus Direct . Acting. Oral . Anticoagulation. in . Patients. . With. . Atrial. . Fibrillation. . J R Coll Physicians Edinb 2019; 49: 143–4 | doi: 10.4997/JRCPE.2019.214IMAGE OF THE QUARTER A 72-year-old female presented with right arm weakness and motor aphasia to our outpatient transient